S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:LGND

Ligand Pharmaceuticals (LGND) Stock Forecast, Price & News

$73.76
-0.52 (-0.70%)
(As of 06/9/2023 ET)
Compare
Today's Range
$73.40
$74.87
50-Day Range
$69.53
$79.33
52-Week Range
$57.77
$109.00
Volume
115,026 shs
Average Volume
110,376 shs
Market Capitalization
$1.27 billion
P/E Ratio
58.54
Dividend Yield
N/A
Price Target
$112.25

Ligand Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
52.2% Upside
$112.25 Price Target
Short Interest
Bearish
5.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
0.66mentions of Ligand Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1.35 M Sold Last Quarter
Proj. Earnings Growth
-23.26%
From $3.74 to $2.87 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

80th out of 987 stocks

Pharmaceutical Preparations Industry

30th out of 477 stocks


LGND stock logo

About Ligand Pharmaceuticals (NASDAQ:LGND) Stock

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Stock News Headlines

Ligand Pharma (LGND) Gets a Buy from Barclays
This Company Is Solving A Multi-Billion Dollar Problem!
This Little Known NASDAQ Stock is Solving a Multi-Billion Dollar Problem!
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Down 5.4%
This Company Is Solving A Multi-Billion Dollar Problem!
This Little Known NASDAQ Stock is Solving a Multi-Billion Dollar Problem!
Ligand Pharmaceuticals (NASDAQ: LGND)
See More Headlines

LGND Price History

LGND Company Calendar

Last Earnings
5/04/2023
Today
6/09/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LGND
CUSIP
53220K50
Employees
154
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$112.25
High Stock Price Forecast
$144.00
Low Stock Price Forecast
$90.00
Forecasted Upside/Downside
+52.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-33,360,000.00
Pretax Margin
46.22%

Debt

Sales & Book Value

Annual Sales
$196.24 million
Cash Flow
$5.02 per share
Book Value
$35.37 per share

Miscellaneous

Free Float
15,477,000
Market Cap
$1.27 billion
Optionable
Optionable
Beta
1.07

Key Executives

  • Todd C. Davis
    Chief Executive Officer & Director
  • Matthew Edward Korenberg
    President & Chief Operating Officer
  • Octavio Espinoza
    Chief Financial Officer
  • Simon Latimer
    Investors Relations Manager
  • Audrey Warfield-Graham
    Chief People Officer













LGND Stock - Frequently Asked Questions

Should I buy or sell Ligand Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LGND shares.
View LGND analyst ratings
or view top-rated stocks.

What is Ligand Pharmaceuticals' stock price forecast for 2023?

4 Wall Street analysts have issued twelve-month price objectives for Ligand Pharmaceuticals' stock. Their LGND share price forecasts range from $90.00 to $144.00. On average, they predict the company's stock price to reach $112.25 in the next year. This suggests a possible upside of 52.3% from the stock's current price.
View analysts price targets for LGND
or view top-rated stocks among Wall Street analysts.

How have LGND shares performed in 2023?

Ligand Pharmaceuticals' stock was trading at $66.80 at the beginning of the year. Since then, LGND shares have increased by 10.3% and is now trading at $73.70.
View the best growth stocks for 2023 here
.

When is Ligand Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our LGND earnings forecast
.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its earnings results on Thursday, May, 4th. The biotechnology company reported $2.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $1.39. The biotechnology company had revenue of $43.98 million for the quarter, compared to the consensus estimate of $33.55 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 3.44% and a net margin of 11.00%. The company's quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.15 earnings per share.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of $4.60-$4.75 for the period, compared to the consensus earnings per share estimate of $3.52. The company issued revenue guidance of $124.00 million-$128.00 million, compared to the consensus revenue estimate of $128.57 million.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.52%), Macquarie Group Ltd. (4.74%), Macquarie Group Ltd. (4.74%), State Street Corp (3.74%), Villere ST Denis J & Co. LLC (2.80%) and Dimensional Fund Advisors LP (2.74%). Insiders that own company stock include Andrew Reardon, Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis.
View institutional ownership trends
.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $73.70.

How much money does Ligand Pharmaceuticals make?

Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.27 billion and generates $196.24 million in revenue each year. The biotechnology company earns $-33,360,000.00 in net income (profit) each year or $1.26 on an earnings per share basis.

How many employees does Ligand Pharmaceuticals have?

The company employs 154 workers across the globe.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826.

This page (NASDAQ:LGND) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -